SCHEMBL4152969

SCHEMBL4152969

c1cc(-c2cncc(NCc3ccc4c(c3)OCO4)c2)ccn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.60
ALDH1A1 P00352 4/20 0.60
GAA P10253 3/20 0.60
KDM4E B2RXH2 3/20 0.60
HSD17B10 Q99714 2/20 0.60
NPSR1 Q6W5P4 2/20 0.60
PABPC1 P11940 1/20 0.60
FYN P06241 1/20 0.53
AURKA O14965 1/20 0.52
FLT1 P17948 1/20 0.48
KDR P35968 1/20 0.48
INSR P06213 1/20 0.48
IGF1R P08069 1/20 0.48
SRC P12931 1/20 0.48
MAPK1 P28482 2/20 0.47
HPGD P15428 2/20 0.47
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
LMNA P02545 1/20 0.47
THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4199234 0.88 FYN (0.54) MAPTALDH1A1GAAKDM4EHSD17B10
SCHEMBL4182276 0.82 FYN (0.62) MAPTALDH1A1GAAKDM4EHSD17B10
SCHEMBL4189206 0.81 MAPT (0.58) MAPTALDH1A1KDM4EFYNINSR
SCHEMBL4187618 0.78 BRAF (0.73) HSD17B10FYNAURKAMEN1KMT2A
SCHEMBL4194265 0.78 AURKA (0.56) MAPTALDH1A1GAAHSD17B10NPSR1
SCHEMBL4192356 0.78 BRAF (0.53) MAPTALDH1A1GAAKDM4EHSD17B10
SCHEMBL4160142 0.78 FYN (0.56) MAPTALDH1A1GAAKDM4EHSD17B10
SCHEMBL4189969 0.77 FYN (0.61) MAPTALDH1A1GAAKDM4EHSD17B10
SCHEMBL4149001 0.76 MEN1 (0.48) MAPTPABPC1FYNKDRMEN1
SCHEMBL4160085 0.76 DYRK1A (0.52) MAPTGAAFYNFLT1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US claimed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP claimed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO claimed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 US disclosed
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US disclosed
US-20090163515-A1 Compounds Which Bind to the Active Site of Protein Kinase Enzymes BIOFOCUS DISCOVERY LTD. 2009-06-25 US disclosed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP disclosed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163515-A1 Compounds Which Bind to the Active Site of Protein Kinase Enzymes ROCK1, ROCK2, CIT MAPT 1507/4885ALDH1A1 4066/4885GAA 1351/4885
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 MAPT 3192/4885ALDH1A1 2624/4885GAA 3346/4885
US-20090196912-A1 Pyridinylamines PRNP, PLPBP, SNCA MAPT 23/4885ALDH1A1 1221/4885GAA 2024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.